Who is sponsoring NCT06786780?

NCT06786780 is sponsored by Chongqing University Cancer Hospital.

What drugs are being tested in NCT06786780?

Interventions in NCT06786780: Drug: Cisplatin.

Is NCT06786780 still recruiting?

NCT06786780 is currently enrolling by invitation. Last updated 26 March 2025.

Last reviewed 2025-03-26 · How we verify

NCT06786780: ECCO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids

ENROLLING BY INVITATION Phase 2 Last updated 26 March 2025

What this trial tests

Phase 2 trial testing Drug: Cisplatin in Cervical Cancer Treated with Pelvic Radiotherapy in 50 participants. Enrolling by invitation.

Timeline

1 January 2023

Primary endpoint
1 June 2025

1 June 2026

Quick facts

Lead sponsor	Chongqing University Cancer Hospital
Phase	Phase 2
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 January 2023
Primary completion	1 June 2025
Estimated completion	1 June 2026
Sites	1 location across China

Drugs / interventions tested

Drug: Cisplatin

Conditions studied

Cervical Cancer Treated with Pelvic Radiotherapy — all drugs for Cervical Cancer Treated with Pelvic Radiotherapy →
Cervical Cancers — all drugs for Cervical Cancers →

Sponsor

Chongqing University Cancer Hospital

Who can join

18 and older, female only, with Cervical Cancer Treated with Pelvic Radiotherapy or Cervical Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, single-center, open-label, Phase II study aimed at assessing the efficacy of organoids in predicting the response to radiotherapy and chemotherapy in cervical cancer

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor Organoid and Microenvironment Cocultures: Implications for Basic and Translational Cancer Research.
Yang J, Cheng C, Luo W, He X, et al · · 2026 · PMID 41987851 · DOI 10.1002/mco2.70741
Recapitulating the tumour microenvironment: advancing personalised radiation therapy through organoid technology.
Lan Z, Liu J, Li L, Yang Y, et al · · 2026 · PMID 41761263 · DOI 10.1186/s13046-026-03655-0
Modeling Drug and Radiation Resistance with Patient-Derived Organoids: Recent Progress, Unmet Needs, and Future Directions for Lung Cancer.
Lee D, Kim Y, Kang DH, Chung C. · · 2025 · PMID 41440014 · DOI 10.3390/cells14241994

Verify or expand the search:

Other Chongqing University Cancer Hospital trials

Trials by the same sponsor.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07425795 — Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of E · Phase 2 · recruiting
NCT07248696 — Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Pro · NA · active not recruiting
NCT07248670 — Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC · Phase 3 · active not recruiting
NCT06981858 — A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advan · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06786780 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongqing University Cancer Hospital
Last refreshed: 26 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06786780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing